Menu Search
Equities

China Dasheng Biotechnology Co

CDBT:PKC

China Dasheng Biotechnology Co

Actions
  • Price (USD)0.05
  • Today's Change0.00 / 0.00%
  • Shares traded4.93k
  • 1 Year change+9.17%
  • Beta1.6274
Data delayed at least 15 minutes, as of Sep 13 2024 20:45 BST.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Financials data is unavailable for this security.

Inc stmt in USDIncome statement in USDView more

Year on year China Dasheng Biotechnology Co has grown net income from a loss of 68.00k to a gain of 4.64m primarily through revenue growth (0.00 to 16.29m). For while the costs associated with cost of goods, selling, general and administrative and debt all increased as a percentage of sales, the -- growth in revenues contributed enough to still see net income improve.
Gross margin47.85%
Net profit margin34.97%
Operating margin33.59%
Return on assets33.10%
Return on equity40.01%
Return on investment41.97%
More ▼

Cash flow in USDView more

In 2008, China Dasheng Biotechnology Co increased its cash reserves by 18.53%, or 244.00k. The company earned 4.10m from its operations for a Cash Flow Margin of 25.14%. In addition the company used 3.92m on investing activities and also paid 927.00k in financing cash flows.
Cash flow per share0.2663
Price/Cash flow per share0.2565
Book value per share0.6408
Tangible book value per share0.5924
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.